Background: In the phase 3 B-LONG study (NCT01027364), prophylaxis with recom-
| INTRODUCTION
Compared with on-demand treatment, prophylactic factor replacement therapy improves clinical outcomes in people with hemophilia, reducing the frequency of bleeding episodes, and improving joint outcomes and quality of life. 1, 2 For prophylaxis in hemophilia B, the use of conventional half-life factor IX (FIX) products requires frequent injections to maintain protective FIX levels. The burden imposed by frequent injections is an important barrier to adherence in individuals with hemophilia treated prophylactically.
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Recombinant FIX Fc fusion protein (rFIXFc; eftrenonacog alfa) is one of the approved extended half-life products for hemophilia B.
rFIXFc is a fusion protein comprising human coagulation FIX covalently bound without a linker to the Fc domain of human immunoglobulin G1 (IgG1) produced in a well-characterized human cell line. The phase 3 B-LONG study demonstrated that prophylaxis with rFIXFc is associated with low annualized bleeding rates (ABRs) in male patients aged ≥12 years with severe hemophilia B. 6 The extension study, B-YOND, has confirmed the long-term safety and efficacy of prophylaxis with rFIXFc
7
; key results upon completion of the B-YOND study are expected in 2018.
The approved indication for rFIXFc in the EU was updated in
July 2017 to include a dosing interval of ≥14 days for use in patients with hemophilia B who are well controlled with rFIXFc administered every 10 days. 5 The aim of the current post-hoc analysis was to characterize long-term experience with extended interval dosing using data up to the second data cut of B-YOND (September 2015).
| METHODS
B-LONG (NCT01027364) was a phase 3, non-randomized, openlabel, multicenter study, with primary and secondary endpoints reported previously. 6 The study enrolled 123 male patients aged ≥12 years with severe hemophilia B (≤2% of normal FIX levels) whose prior treatment regimen was either prophylaxis or on demand.
In B-LONG, patients were assigned to one of four treatment groups: 
| RESULTS AND DISCUSSION
Twenty-two patients received rFIXFc prophylaxis with a dos- Table 1) .
The majority of patients (18 of 22) whose dosing interval was extended to ≥14 days were on interval-adjusted prophylaxis
Essentials
• Prophylactic replacement of coagulation factor IX (FIX) is recommended in severe hemophilia B.
• Recombinant FIX Fc fusion protein (rFIXFc) is effective and well tolerated.
• Phase 3 post-hoc analysis shows that some patients are well controlled with rFIXFc every ≥14 days.
• A ≥14-day rFIXFc dosing interval may help reduce treatment burden for well-controlled patients.
prior to the extension ( The majority of patients treated prophylactically appeared well controlled and experienced zero bleeds during the period before their dosing interval was extended to ≥14 days. However, 5 of 22 patients returned permanently to a dosing interval of <14 days due to a PK result (n = 1), patient request (n = 3: two of which were for personal reasons, the third due to bleeding), or repeated bleeding (elbow; n = 1). Among these five patients, one had previously been treated on-demand and three others had either a very short or no observation period on rFIXFc prior to extending the dosing interval and it is therefore uncertain if these patients truly were well controlled before extending their dosing interval to ≥14 days.
The remaining 17 of the 22 patients (77.3%) continued on a dosing ) are not presented because of differences in sampling profiles. interval of ≥14 days at the time of the second interim data cut, although three of these 17 patients had had a temporary reduction (50, 30, and 22 days) in the dosing interval to <14 days at some point before the data cut because of bleeding (n = 1), repeated bleeding into the knee following arthroscopy (n = 1) and PK result (n = 1).
TA B L E 2 Exposure to rFIXFc on a ≥14-day dosing interval
The ABR during the period with a ≥14-day dosing interval was estimated for patients on prior prophylaxis who had an observation period of ≥6 months on the extended dosing regimen. These patients had a median (IQR) overall ABR of 1.6 (0.6-2.7) (Table 3) , which is consistent with the ABR reported for the overall study population. prophylaxis the interim analysis of B-YOND.
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The median (IQR) spontaneous ABR during the period with a ≥14-day dosing interval was 0.7 (0.3-1.1) ( Table 3) In total, four patients were excluded from the ABR calculation; two because they had an observation period that was too short (28 and 57 days) to obtain robust estimates of ABR and an additional two patients because they had received on-demand treatment before the dosing interval was changed to ≥14 days.
A total of 120 bleeding episodes in 22 patients occurred over 744 patient months of exposure while on a ≥14-day dosing interval.
Approximately 60% of the bleeds occurred during the first 10 days since previous dosing. The majority of bleeding episodes (114 [95%])
were controlled with either one or two injections. The median (IQR) total rFIXFc dose used to treat a bleed was 56.3 (37-99.1) IU/kg.
The adverse event profile was consistent with that expected in a hemophilia B population, and no new safety concerns were identified, compared with the overall populations in B-LONG 6 or B-YOND. There were no reports of serious allergic reactions, anaphylaxis, vascular thrombotic events, or development of inhibitors. 6, 7 In conclusion, these data confirm that patients who were well controlled on a 10-day dosing interval of rFIXFc prophylaxis remained well controlled with low ABRs when treated long-term on a ≥14-day dosing interval, and the treatment was well tolerated. A rFIXFc dosing interval of ≥14 days allows for broader treatment flexibility and treatment individualization compared with conventional FIX products, and further reduces the burden for patients, potentially positively impacting adherence. This analysis included patients who were on prophylaxis before extending the dosing interval to ≥14 day (ie, the two patients receiving ondemand treatment were excluded), and who had been observed for ≥6 mo (thereby excluding an additional two patients).
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